Norton Clark Hospital, LLC
Norton Clark Hospital, LLC was paid $19.62M by Medicaid between Jan 2018 and Nov 2024, across 108 billing codes. Its largest line is 99285, emergency room visit (most serious) — 23% of everything it billed.
JEFFERSONVILLE, IN 47130
Next to other General Acute Care Hospital providers in Indiana
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 58,185 | $889K | |
| 2019 | 69,628 | $2.24M | |
| 2020 | 53,175 | $2.47M | |
| 2021 | 64,294 | $3.50M | |
| 2022 | 68,738 | $4.10M | |
| 2023 | 57,869 | $3.54M | |
| 2024incomplete | 46,983 | $2.88M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 37,044 | 29,413 | $4.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 30,590 | 25,070 | $3.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 25,139 | 20,953 | $2.83M |
| 71046 | Radiologic examination, chest; 2 views | 7.9% | 16,041 | 12,726 | $1.54M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.5% | 20,694 | 15,490 | $1.07M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.9% | 21,209 | 16,564 | $957K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 6,634 | 5,480 | $818K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.8% | 1,256 | 365 | $551K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 5,751 | 4,588 | $463K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 923 | 741 | $303K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 3,997 | 2,847 | $283K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 2,619 | 2,032 | $267K |
96 more codes
| 90837 | Psychotherapy session, about an hour | 1.2% | 3,370 | $239K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.0% | 12,534 | $202K |
| 80053 | Comprehensive metabolic panel | 1.0% | 41,147 | $199K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,574 | $186K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,222 | $161K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,356 | $133K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,231 | $122K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,100 | $114K |
| 97597 | <1% | 1,014 | $112K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,713 | $90K |
| 84484 | <1% | 13,767 | $81K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,733 | $80K |
| 62323 | <1% | 117 | $64K | |
| 83880 | <1% | 3,608 | $59K | |
| G0378 | Hospital observation service, per hour | <1% | 576 | $51K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,862 | $46K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,566 | $44K |
| 83690 | <1% | 14,514 | $40K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,023 | $34K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,884 | $33K |
| 81025 | <1% | 7,568 | $32K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $20K |
| 87400 | <1% | 3,860 | $19K | |
| 87430 | <1% | 2,680 | $18K | |
| 81001 | <1% | 11,844 | $17K | |
| 81003 | <1% | 13,088 | $14K | |
| 94761 | <1% | 426 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,198 | $10K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 105 | $7K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 423 | $6K |
| 76830 | Ultrasound, transvaginal | <1% | 26 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 26 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,520 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,909 | $5K |
| 87081 | <1% | 1,241 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 220 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 220 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 364 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 27 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 51 | $3K |
| 80061 | Lipid panel | <1% | 310 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 199 | $2K |
| 82075 | <1% | 197 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $1K |
| 85730 | <1% | 878 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 64 | $1K |
| 83735 | <1% | 408 | $1K | |
| 80361 | <1% | 38 | $983.37 | |
| 85610 | <1% | 996 | $904.76 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,905 | $863.59 |
| 85027 | <1% | 203 | $742.50 | |
| 76000 | <1% | 27 | $700.00 | |
| 82962 | <1% | 1,017 | $651.29 | |
| 84436 | <1% | 95 | $497.01 | |
| 87070 | <1% | 136 | $486.56 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,782 | $461.50 |
| 87150 | <1% | 12 | $422.13 | |
| 80076 | <1% | 78 | $402.33 | |
| A9270 | Non-covered item or service | <1% | 3,012 | $268.01 |
| 82948 | <1% | 538 | $261.51 | |
| 73630 | <1% | 15 | $244.05 | |
| 82550 | <1% | 45 | $211.48 | |
| 85379 | <1% | 48 | $209.28 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13 | $199.51 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 59 | $166.10 |
| 83970 | <1% | 22 | $159.29 | |
| 73610 | <1% | 18 | $126.08 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 32 | $119.81 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 475 | $112.41 |
| 84439 | <1% | 12 | $108.33 | |
| 84702 | <1% | 15 | $93.36 | |
| 87186 | <1% | 43 | $77.47 | |
| 87077 | <1% | 23 | $69.27 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 869 | $64.44 |
| 72110 | <1% | 17 | $63.32 | |
| 87210 | <1% | 13 | $28.20 | |
| 82570 | <1% | 23 | $19.98 | |
| 84100 | <1% | 23 | $18.27 | |
| 84156 | <1% | 23 | $14.14 | |
| 87205 | <1% | 15 | $5.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 730 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 185 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 321 | $0.00 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 15 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 106 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 96 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 57 | $0.00 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | 0% | 71 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 16 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 50 | $0.00 |
| A6260 | Wound cleansers, any type, any size | 0% | 17 | $0.00 |
| 80320 | 0% | 14 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 106 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 345 | $0.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 357 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 55 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.